Inhibition of secretory phospholipase A2 activity attenuates acute cardiogenic pulmonary edema induced by isoproterenol infusion in mice after myocardial infarction

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 4, 2010, Pages 369-378

  Kawabata, Kenichi ^a   Fujioka, Daisuke ^a   Kobayashi, Tsuyoshi ^a   Saito, Yukio ^a   Obata, Jun Ei ^a   Nakamura, Takamitsu ^a   Yano, Toshiaki ^a   Watanabe, Kazuhiro ^a   Watanabe, Yosuke ^a   Mishina, Hideto ^a   Kugiyama, Kiyotaka ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

acute cardiogenic pulmonary edema; eicosanoids; mouse model; secretory phospholipase A2

Indexed keywords

4 BROMOPHENACYL BROMIDE; [3 AMINOOXALYL 1 BENZYL 2 ETHYL 6 METHYL 1H INDOL 4 YLOXY] ACETIC ACID METHYL ESTER; ENZYME INHIBITOR; ISOPRENALINE; LEUKOTRIENE B4; LY 329722; LY 374388; MESSENGER RNA; MYELOPEROXIDASE; PHOSPHOLIPASE A2; SODIUM [3 AMINOOXALYL 1 BENZYL 2 ETHYL 6 METHYL 1H INDOL 4 YLOXY] ACETIC ACID; THROMBOXANE A2; UNCLASSIFIED DRUG;

ACUTE CARDIOGENIC LUNG EDEMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BODY WEIGHT; CAPILLARY PERMEABILITY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART INFARCTION; HEART RATE; HEMODYNAMIC PARAMETERS; IMMUNOHISTOCHEMISTRY; LUNG BLOOD VESSEL; LUNG DISEASE; LUNG WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; INDOLEACETIC ACIDS; INFUSIONS, INTRAVENOUS; ISOPROTERENOL; LEUKOTRIENE B4; LUNG; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; PHOSPHOLIPASES A2, SECRETORY; PULMONARY EDEMA; THROMBOXANE B2;

EID: 77958498868     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181ef1aab     Document Type: Article

References (30)

1. Ware LB, Matthay MA. Acute pulmonary edema. N Engl J Med. 2005; 353:2788-2796.
2. Gropper MA, Wiener-Kronish JP, Hashimoto S. Acute cardiogenic pulmonary edema. Clin Chest Med. 1994;15:501-515.
3. Nakos G, Pneumatikos J, Tsangaris I, et al. Proteins and phospholipids in BAL from patients with hydrostatic pulmonary edema. Am J Respir Crit Care Med. 1997;155:945-951.
4. Milo O, Cotter G, Kaluski E, et al. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol. 2003;92:222-226.
5. Cohen AB, Stevens MD, Miller EJ, et al. Neutrophil-activating peptide-2 in patients with pulmonary edema from congestive heart failure or ARDS. Am J Physiol. 1993;264:L490-L495.
6. Geppert A, Zorn G, Heinz G, et al. Soluble selectins in the pulmonary and systemic circulation in acute cardiogenic and non-cardiogenic pulmonary failure. Intensive Care Med. 2001;27:521-527.
7. Haupt MT. Cardiogenic pulmonary edema: an inflammatory disorder? Crit Care Med. 2003;31:1282-1283.
8. De Pasquale CG, Arnolda LF, Doyle IR, et al. Prolonged alveolocapillary barrier damage after acute cardiogenic pulmonary edema. Crit Care Med. 2003;31:1060-1067.
9. 2 regulation of arachidonic acid mobilization. FEBS Lett. 2002;531:2-6.
10. 2. Biol Pharm Bull. 2004;27:1158-1164.
11. 2. Prostaglandins Leukot Essent Fatty Acids. 2003;69:87-97.
12. 2\a mediator between proximal and distal effectors of inflammation. Immunol Today. 1991; 12:143-146.
13. 2 gene family in mammals. J Biol Chem. 1997;272:17247-17250.
14. 2. Cloning, tissue distribution, and functional expression of two novel mouse group II enzymes. J Biol Chem. 1999;274: 31195-31202.
15. 2s. Biochim Biophys Acta. 2000;1488:159-166.
16. Seeds MC, Jones KA, Duncan Hite R, et al. Cell-specific expression of group X and group V secretory phospholipases A (2) in human lung airway epithelial cells. Am J Respir Cell Mol Biol. 2000;23:37-44.
17. 2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells. Biochem J. 2005;387:27-38.
18. 2 in allergen-induced airway inflammation and remodeling in a mouse asthma model. J Exp Med. 2007;204:865-877.
19. 2 activity attenuates lipopolysaccharide-induced acute lung injury in a mouse model. Experimental Lung Research. 2010;36: 191-200.
20. 2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Crit Care Med. 2001;29:719-727.
21. 2 gene in inbred mouse strains. J Biol Chem. 1995;270:22378-22385.
22. 2-deficient mice. Circulation. 2008;117:2977-2985.
23. Dodd-O JM, Hristopoulos ML, Faraday N, et al. Effect of ischemia and reperfusion without airway occlusion on vascular barrier function in the in vivo mouse lung. J Appl Physiol. 2003;95:1971-1978.
24. Mergner WJ, Trump BF. Hemodynamic disorders. In: Rubin E, Farber JL, eds. Pathology, 2nd ed. Philadelphia: JB Lippincott Company; 1994: 263-287.
25. Elsner D, Riegger GA. Characteristics and clinical relevance of animal models of heart failure. Curr Opin Cardiol. 1995;10:253-259.
26. 2 transgenic mice spontaneously develop inflammation. Biochem J. 2009; 421:17-27.
27. 2. Nat Immunol. 2000;1:42-46.
28. 2 modulates phagosome maturation and regulates the innate immune response against Candida albicans. J Immunol. 2009;182:4891-4898.
29. 2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med. 2005;33: 1741-1748.
30. 2beta, precipitating ventricular tachyarrhythmias in transgenic mice: rescue of the lethal electrophysiologic phenotype by mechanism-based inhibition. J Biol Chem. 2003;278:22231-22236.